Novo Nordisk and IBM partner to build diabetes care solutions on the Watson Health Cloud

Bagsværd, Denmark and Armonk, US, 10 December 2015 - Novo Nordisk and IBM Watson Health today announced that the two companies will work together to create diabetes solutions built on the Watson Health Cloud. The agreement combines Novo Nordisk's deep understanding of diabetes with IBM's leadership in cognitive computing.

The companies will explore possibilities for improved diabetes care via insights from real-time, real-world evidence of Novo Nordisk diabetes treatments and devices. By harnessing the potential of the Watson Health Cloud, Novo Nordisk aims to further advance its offerings to people living with diabetes and their healthcare professionals.Commenting on the agreement, Jakob Riis, executive vice president, Novo Nordisk said: "Working with ambitious partners like IBM Watson Health helps us explore the opportunities presented by an increasingly digitalised healthcare system. We aim to leverage our combined capabilities to improve the lives of people with diabetes by making the management of the condition more simple, effective and measurable."

IBM Watson is the first commercially available cognitive computing platform and represents a new era of computing. The platform, delivered through the cloud, processes vast amounts of big data to uncover patterns and insights, understands complex questions posed in natural language, proposes evidence-based answers, and learns from each interaction. The Watson Health Cloud is a development platform for health and wellness solutions.

"IBM is excited to work with Novo Nordisk, a global leader in diabetes, to help the company create new e-health solutions on the Watson Health Cloud - accessing cognitive computing to help personalise care," said Deborah DiSanzo, general manager of IBM Watson Health.

About Diabetes

The International Diabetes Federation (IDF) estimates that 415 million people have diabetes today - a figure that IDF estimates could rise to 642 million by 2040. Complications from poorly managed diabetes include cardiovascular disease, kidney disease, nerve damage and blindness. Diabetes and its complications account for 12% of global health expenditure ($673 billion US dollars).1

About Novo Nordisk

Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: haemophilia, growth disorders and obesity. Headquartered in Denmark, Novo Nordisk employs approximately 40,300 people in 75 countries and markets its products in more than 180 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.comFacebookTwitterLinkedIn,YouTube

About IBM Watson Health

In April 2015, IBM launched IBM Watson Health and the Watson Health Cloud platform. The new unit will help improve the ability of doctors, researchers and insurers to innovate by surfacing insights from the massive amount of personal health data being created and shared daily. The Watson Health Cloud allows this information to be de-identified, shared and combined with a dynamic and constantly growing aggregated set of data such as clinical, research and social health data.For more information on IBM Watson Health, visit:

Check out the IBM Watson press kit at:

Join the conversation at #ibmwatson and #watsonhealth. Follow Watson onFacebook and see Watson on YouTube and Flickr.

Further information

Adam Pittard +45 3075 5056 [email protected]
Ken Inchausti (US) +1 267 809 7552 [email protected]
Peter Hugreffe Ankersen +45 3075 9085 [email protected]
Daniel Bohsen +45 3079 6376 [email protected]
Melanie Raouzeos +45 3075 3479 [email protected]
Kasper Veje +45 3079 8519 [email protected]
Frank Daniel Mersebach (US) +1 609 235 8567 [email protected]


  1. International Diabetes Federation, IDF Atlas, 7th edition, 2015.